2026 Bio Parts, Materials & Equipment (PME) Policy Landscape
Bio PME localization is emerging as the top priority in Korea's 2026 bio industry policy. The Ministry of Trade, Industry and Energy's R&D budget is expanding roughly threefold, from KRW 23.6 billion in 2023 to KRW 70.3 billion in 2026, reflecting a nationwide push to overcome the harsh reality of Korean products holding just 2% of the global bio PME market.
The Bio PME Solidarity and Cooperation Council, now in its 8th year, will be significantly expanded in 2026. The council will move beyond its original 16 anchor buyers to actively include small and medium-sized demand and supply companies, establishing a full-cycle package covering R&D, validation, investment, and supply chain.
Real-World Barriers for Demand Companies
The main reason domestic bio PME adoption has lagged is not technology itself but switching cost and risk.
Revalidation burden: Switching core materials such as media, resins, or filters requires full process revalidation, which typically takes 3–6 months and costs hundreds of thousands of dollars per production lineChange control risk: Processes already registered with the FDA or EMA require regulatory consultation to modify, and contracts with global pharma clients often impose strict change-control clausesLimited validation data: Domestic products frequently lack long-term stability and reproducibility data, causing buyers to defer adoption decisionsStructure of the Government Package Support
The 2026 bio PME program is not a single R&D grant but a full-cycle package.
R&D Stage
National Research Foundation 2nd call for Bio & Medical Technology Development Program supports localization R&DPriority given to PME for next-generation modalities such as cell & gene therapy (CGT), mRNA, and ADCValidation & Adoption Stage
Demand company test program partially reimburses validation costs when a domestic product is applied to a real manufacturing processMatching routes provided to members of the Solidarity CouncilInvestment & Supply Chain Stage
Linkage with bio mother funds and Korea Development Bank policy financingOverseas market entry support and global supply chain restructuring programsStrategy for SME Supply Companies
For supply companies, securing demand customers is the decisive success factor.
Join the Solidarity Council: Apply early in the 2026 expansion round to secure matching opportunitiesLeverage bio clusters: Build validation networks with Songdo, Osong, and Daegu-Gyeongbuk advanced medical complexesAccumulate localization references: Co-run validation projects with 1–2 early adopters to build long-term stability data and convert it into a marketing assetPlan R&D proposals: Form consortia with demand companies and prepare proposals aligned with the NRF 2nd callStrategy for SME Demand Companies
For demand companies, risk diversification is key.
Phased adoption: Pilot on non-critical processes first, then scale to core processesUse validation cost reimbursement: Government support can offset switching costs by 50% or morePre-consult regulatory change control: Develop a change-control scenario and open consultation channels with regulators before adopting domestic materialsKITIM Consulting
Bio PME localization sits at the intersection of technology, regulation, and commercialization. Backed by 150+ consulting engagements, KITIM (Korea Institute of Technology Innovation Management) delivers end-to-end advisory — from localization R&D proposal design and GMP change control & validation strategy to demand-supply matching and participation in government validation programs. If your SME is considering joining the 2026 bio PME package support, contact KITIM today for an expert consultation.
